EMA Withdrawn: Jetrea (ocriplasmin) — Inceptua AB

View source ↗

Summary

The EMA has withdrawn Jetrea (ocriplasmin) from the European market; the marketing authorization holder is Inceptua AB, with the withdrawal decision made in 202…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Macular Hole
• Vitreomacular Adhesion

Drugs mentioned

• Jetrea (ocriplasmin)

Snippet

Status: Withdrawn. Therapeutic area: Retinal Diseases. MAH: Inceptua AB. Decision date: 11/12/2020